Incidence and classification of neointimal proliferation and in-stent restenosis in post-stenting patients at 1-year interval: findings from non-invasive coronary computed tomography angiography.

OBJECTIVES To evaluate the incidence of coronary in-stent restenosis (ISR) and neointimal proliferation by coronary CT angiography (CCTA) at 1-year follow-up in asymptomatic patients. METHODS 234 patients (mean age: 67 ± 10.2 years, range 39-88 years, 180 males and 54 females) with 379 stents were prospectively enrolled in this study. Binary ISR was classified by CCTA into 4 types using Mehran classification. Neointimal proliferation was similarly classified into focal and diffuse types. All patients with CCTA-revealed ISR or neointimal proliferation underwent further invasive coronary angiography (ICA) for validation. Fisher's exact test was used for comparison. RESULTS ICA revealed patent stents with neointimal proliferation in 39 patients (16.7%, 39/234) and binary ISR in 23 patients (9.8%, 23/234). Lesion-based analysis showed 12 type I ISR lesions, 4 type II ISR lesions, 1 type III ISR lesion and 7 type IV ISR lesions. Among cases with neointimal proliferation, 27 lesions were classified as focal type whereas 13 lesions were classified as diffuse type. Patients with diabetes mellitus were associated with higher incidence of CCTA-revealed neointimal proliferation (21/77 vs. 18/157, p=0.002) as well as ISR (12/77 vs. 11/157, p=0.038), compared to patients without diabetes. CCTA was found to have good diagnostic performance for neointimal proliferation and ISR detection as well as classification, with an overall accuracy of 84.4% (54/64). CONCLUSIONS Silent ISR as well as neointimal proliferation is not uncommon findings in asymptomatic post-stenting patients at 1-year interval, as revealed by CCTA. Patients with diabetes are prone to have higher incidence of neointimal proliferation.

[1]  Deepak L. Bhatt,et al.  Bare metal stent restenosis is not a benign clinical entity. , 2006, American heart journal.

[2]  M. Pfisterer,et al.  Long-term outcome of patients with silent versus symptomatic ischemia six months after percutaneous coronary intervention and stenting. , 2003, Journal of the American College of Cardiology.

[3]  G. Stone,et al.  Angiographic patterns of in-stent restenosis: classification and implications for long-term outcome. , 1999, Circulation.

[4]  Antonio Colombo,et al.  Mechanism of Late In-Stent Restenosis After Implantation of a Paclitaxel Derivate–Eluting Polymer Stent System in Humans , 2002, Circulation.

[5]  Gary S Mintz,et al.  In-stent restenosis in the drug-eluting stent era. , 2010, Journal of the American College of Cardiology.

[6]  Benno J. Rensing,et al.  Sustained Suppression of Neointimal Proliferation by Sirolimus-Eluting Stents: One-Year Angiographic and Intravascular Ultrasound Follow-Up , 2001, Circulation.

[7]  Patrick W Serruys,et al.  Evaluation of four-year coronary artery response after sirolimus-eluting stent implantation using serial quantitative intravascular ultrasound and computer-assisted grayscale value analysis for plaque composition in event-free patients. , 2005, Journal of the American College of Cardiology.

[8]  P. Serruys,et al.  Clinical and Angiographic Factors Associated With Asymptomatic Restenosis After Percutaneous Coronary Intervention , 2001, Circulation.

[9]  P. Serruys,et al.  Clinical outcomes of the Resolute zotarolimus-eluting stent in patients with in-stent restenosis: 2-year results from a pooled analysis. , 2013, JACC. Cardiovascular interventions.

[10]  Patrick W Serruys,et al.  New frontiers in cardiology: drug-eluting stents: Part I. , 2003, Circulation.

[11]  M. Kimura,et al.  A comparison of clinical presentations, angiographic patterns and outcomes of in-stent restenosis between bare metal stents and drug eluting stents. , 2010, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[12]  Minghua Li,et al.  Angiographic patterns of in-stent restenosis classified by computed tomography in patients with drug-eluting stents: correlation with invasive coronary angiography , 2012, European Radiology.

[13]  Jeffrey W Moses,et al.  Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. , 2003, The New England journal of medicine.

[14]  M. Trusz‐Gluza,et al.  Risk factors of asymptomatic restenosis in patients with first anterior ST elevation myocardial infarction treated by primary percutaneous coronary intervention. , 2010, Kardiologia polska.

[15]  Simon Wandel,et al.  Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis , 2007, The Lancet.

[16]  H. Fujita,et al.  Diagnostic accuracy of coronary in-stent restenosis using 64-slice computed tomography: comparison with invasive coronary angiography. , 2007, Journal of the American College of Cardiology.

[17]  P. Serruys,et al.  Peristent Remodeling and Neointimal Suppression 2 Years After Polymer-Based, Paclitaxel-Eluting Stent Implantation: Insights From Serial Intravascular Ultrasound Analysis in the TAXUS II Study , 2005, Circulation.

[18]  Minghua Li,et al.  In vivo evaluation of stent patency by 64-slice multidetector CT coronary angiography: shall we do it or not? , 2012, The International Journal of Cardiovascular Imaging.

[19]  New Frontiers in Cardiology Drug-Eluting Stents: Part II Clinical Cardiology: New Frontiers , 2022 .

[20]  R. Choussat,et al.  In-stent restenosis: long-term outcome and predictors of subsequent target lesion revascularization after repeat balloon angioplasty. , 2000, Journal of the American College of Cardiology.

[21]  V. Legrand,et al.  Drug-eluting stents: meta-analysis in diabetic patients. , 2004, European heart journal.

[22]  A. Schoenenberger,et al.  Effects of percutaneous coronary interventions in silent ischemia after myocardial infarction: the SWISSI II randomized controlled trial. , 2007, JAMA.

[23]  Michael Fiechter,et al.  First in vivo head-to-head comparison of high-definition versus standard-definition stent imaging with 64-slice computed tomography , 2013, The International Journal of Cardiovascular Imaging.

[24]  Gregg W. Stone,et al.  A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease , 2004 .